	US 12,435,154 B2
	Bispecific antibodies against CD3 and CD20
Tahamtan Ahmadi, Rydal, PA (US); Manish Gupta, Skillman, NJ (US); Tommy Li, Edison, NJ (US); Roberto Oliveri, Copenhagen (DK); Dena Demarco, Chatham, NJ (US); Ida Hiemstra, Utrecht (NL); Christopher Chiu, Warren, NJ (US); Brian Elliott, Hoboken, NJ (US); and Ada Azaryan, North Bethesda, MD (US)
Assigned to GENMAB A/S, Valby (DK)
Filed by GENMAB A/S, Valby (DK)
Filed on May 7, 2021, as Appl. No. 17/314,946.
Claims priority of provisional application 63/121,690, filed on Dec. 4, 2020.
Claims priority of provisional application 63/078,667, filed on Sep. 15, 2020.
Claims priority of provisional application 63/022,212, filed on May 8, 2020.
Prior Publication US 2021/0371538 A1, Dec. 2, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 31/573 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2887 (2013.01) [A61K 31/573 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 16/2809 (2013.01); A61K 39/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01)]

29 Claims

1. A method of treating a B-cell non-Hodgkin lymphoma (B-NHL) in a human subject, the method comprising subcutaneously administering a dose of 0.16 mg of epcoritamab to the subject on day one (1) of treatment and subcutaneously administering a dose of 0.8 mg of epcoritamab to the subject on day eight (8) of treatment,

wherein the subject does not experience cytokine release syndrome (CRS) or experiences manageable cytokine release syndrome of grade 1 or grade 2, and

wherein after day eight (8) of treatment epcoritamab is subcutaneously administered in intervals to the subject until progressive disease develops or unacceptable toxicity occurs.